Please assess the completion status of the following clinical trial:

Trial Title: Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Has previously documented chronic hepatitis C genotype 1 (CHC GT 1) infection~* Has hepatitis C virus (HCV) ribonucleic acid (RNA value) ≥10,000 IU/mL~* Body weight ≥40 kg (88 lbs) and ≤125 kg (275 lbs)~* Absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs and symptoms of decompensated liver disease~* Had a liver biopsy within 3 years of screening or between screening and Day 1 with histology consistent with CHC and no evidence of cirrhosis or hepatocellular carcinoma or no other cause for chronic liver disease (for participants with compensated cirrhosis, any liver biopsy demonstrating cirrhosis regardless of length of time since biopsy)~* Female of childbearing potential or a male with female sexual partner who is of childbearing potential agrees to use two acceptable methods of birth control from at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations~* For participants with compensated cirrhosis, evidence of cirrhosis without evidence of hepatocellular carcinoma (confirmed by ultrasound within 4 weeks prior)~Exclusion Criteria:~* Is pregnant, breastfeeding, or plans to become pregnant or donate eggs~* Is human immunodeficiency virus (HIV) positive or known to be co-infected with hepatitis B virus~* Has received prior approved or investigational treatment for hepatitis C~* Has evidence of hepatocellular carcinoma or is under evaluation for hepatocellular carcinoma~* For participants with compensated cirrhosis: alphafetoprotein level of ≥100 ng/mL~* Has evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years~* Has evidence or history of chronic hepatitis not caused by HCV~* Is diabetic and/or hypertensive with clinically significant ocular examination findings: retinopathy, cotton wool spots, optic nerve disorder, retinal hemorrhage, or any other clinically significant abnormality~* Has any known medical condition that could interfere with participation in and completion of the study~* Pre-existing psychiatric condition including but not limited to moderate or severe depression, suicidal or homicidal ideation or attempt, schizophrenia, psychosis, bipolar disorder, post traumatic stress disorder, or mania~* Is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent~* Member or family member of study staff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Grazoprevir 100 mg (Type: EXPERIMENTAL): TN non-cirrhotic (NC) participants receive Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
- Grazoprevir 200 mg (Type: EXPERIMENTAL): TN NC participants receive Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
- Grazoprevir 400 mg (Type: EXPERIMENTAL): TN NC participants receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
- Grazoprevir 800 mg (Type: EXPERIMENTAL): TN NC participants receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
- Boceprevir 800 mg (Type: ACTIVE_COMPARATOR): TN NC participants start a 4 week lead-in with Peg-IFN + RBV, then receive Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.
- Grazoprevir 400 mg/100 mg (Type: EXPERIMENTAL): As the result of an interim analysis, TN NC participants assigned to the 400 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
- Grazoprevir 800 mg/100 mg (Type: EXPERIMENTAL): As the result of an interim analysis, TN NC participants assigned to the 800 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
- OL Grazoprevir 100 mg (Type: EXPERIMENTAL): TN cirrhotic participants receive open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete